RegeneRx Biopharmaceuticals, Inc. (RGRX)

Check out top investors' recommendation for RGRX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of molecules for tissue and organ repair. The company develops its product candidates based on Thymosin beta 4 (Tß4), an amino acid peptide. Its products include RGN-259, a topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology that has completed the Phase IIa exploratory clinical trial; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications treated by systemic administration that has completed Phase I clinical trial; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue that is in Phase II clinical trial. RegeneRx Biopharmaceuticals, Inc. also seeks to identify and evaluate Tß4 peptide fragments and derivatives used as components in cosmeceutical and consumer products. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Ram Selvaraju Aegis Capital Buy   Nov 01, '17     1.50  Nov 01, '18  N/A 
Ram Selvaraju Aegis Capital Buy   Aug 29, '17     2.00  Aug 29, '18  N/A 
Ram Selvaraju Aegis Capital Buy   Jul 28, '17     2.00  Jul 28, '18  N/A 
Ram Selvaraju Aegis Capital Buy   May 19, '17     2.00  May 19, '18  N/A 
Ram Selvaraju Aegis Capital Buy   Mar 31, '17     2.00  Mar 31, '18  N/A